Medical Research Finder

Start
Features
Free trial / FAQ

Researchers
Physicians
Pharmacists
Ecotrophologists
Product Managers
in Health Industries

Loading…

© 2026 meRfi®

Medical Research Finder

Legal Notice
Privacy
Terms of Use

meRfi® Microbiome - The Digital Gut Microbiome Reference (incl. AI Chat)
Prebiotics, Probiotics, FMT / Manipulators of the Intestinal Microbiota

AuthorsReferences (Sources)

AuthorsReferences (Sources)

meRfi® AI Chat

Chemotherapy (CT) + Immune Checkpoint Inhibitors (ICIs) & Non-Small-Cell-Lung-Cancer (NSCLC)

Welcome to meRfi Microbiome!

Please register to continue your trial period!

meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.

Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.

Start your free trial and transform your understanding of the gut microbiota today!

Register for a free trial

Navigation

Contents

First-line Chemo + ICIs is superior to Chemo + Bev in advanced non-squamous non-small-cell lung cancer except for patients with liver metastasis.
Jiang et al. 2022 Immunotherapy 14: 445-457

Chemotherapy can act as a priming therapy to increase a tumor’s response to immunotherapy. We aim through this review to explain the mechanism behind ICI resistance and the value of chemotherapy in escaping this resistance
Zouein et al. 2022 Immunotherapy 14: 155-167

see also:
[Atezolizumab + Carboplatin + Nab-paclitaxel / Protein-bound paclitaxel & Non-small-cell lung cancer (NSCLC)](brain://rNq4O9m9NE--cQfKl0TssQ/AtezolizumabCarboplatinNabpaclitaxel…

References (Sources)

First-line chemotherapy plus immune checkpoint inhibitors or bevacizumab in advanced non-squamous non-small-cell lung cancer without EGFR mutations or ALK fusions
Jiang et al. 2022 Immunotherapy 14: 445-457
Meta-Analysis
Pembrolizumab plus chemotherapy for first-line treatment of metastatic nonsquamous non-small-cell lung cancer: a network meta-analysis
Frederickson et al. 2019
Meta-Analysis
Review
The combination of immune checkpoint inhibitors and chemotherapy in advanced non-small-cell lung cancer: the rational choice
Zouein et al. 2022 Immunotherapy 14: 155-167
Review
The interaction of immune checkpoint inhibitor plus chemotherapy in non-small-cell lung cancer: subadditivity, additivity or synergism?
Rassy et al. 2019 Immunotherapy 11: 913–920

AI Chat

7/1/2026

Chat with our artificial intelligence: